Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Ogba, Ndiya ^a   Manning, Nicole G ^a   Bliesner, Brian S ^a   Ambler, S Kelly ^a   Haughian, James M ^a   Pinto, Mauricio P ^a   Jedlicka, Paul ^b   Joensuu, Kristiina ^c   Heikkilä, Päivi ^c   Horwitz, Kathryn B ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 5; ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; VIMENTIN; ESTROGEN; GESTAGEN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER METASTASIS; MCF 7 CELL LINE; MICROMETASTASIS; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BONE TUMOR; BRAIN TUMOR; BREAST TUMOR; CANCER TRANSPLANTATION; DISEASE COURSE; DRUG EFFECTS; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; KERATIN-5; LIVER NEOPLASMS; LUNG NEOPLASMS; MCF-7 CELLS; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROGESTERONE; PROGESTINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84924249372     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0489-4     Document Type: Article

References (56)

1. Dunnwald LK, Rossing MA, Li CI: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6.
2. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
3. Demicheli R, Biganzoli E, Ardoino I, Boracchi P, Coradini D, Greco M, Moliterni A, Zambetti M, Valagussa P, Gukas ID, Bonadonna G: Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci 2010, 101:826-830.
4. Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK: Metastasis dormancy in estrogen receptor-positive breast cancer. J Clin Oncol 2013, 19:6389-6397.
5. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277.
6. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003, 100:15901-15905.
7. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN: Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012, 367:435-444.
8. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, et al: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010, 7:e1000279.
9. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253.
10. Farhat GN, Walker R, Buist DS, Onega T, Kerlikowske K: Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 2010, 28:5140-5146.
11. Sartorius CA, Harvell DM, Shen T, Horwitz KB: Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res 2005, 65:9779-9788.
12. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE: Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802.
13. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA: Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 2008, 105:5774-5779.
14. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R: Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
15. Horwitz KB, Sartorius CA: Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008, 93:3295-3298.
16. Wei S, Li Y, Siegal GP, Hameed O: Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Ann Diagn Pathol 2011, 15:79-83.
17. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL: Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17:1514-1520.
18. Ganapathy V, Banach-Petrosky W, Xie W, Kareddula A, Nienhuis H, Miles G, Reiss M: Luminal breast cancer metastasis is dependent on estrogen signaling. Clin Exp Metastasis 2012, 29:493-509.
19. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, Chen EI, Lyden D, Bissell MJ: The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013, 15:807-817.
20. Marlow R, Honeth G, Lombardi S, Cariati M, Hessey S, Pipili A, Mariotti V, Buchupalli B, Foster K, Bonnet D, Grigoriadis A, Rameshwar P, Purushotham A, Tutt A, Dontu G: A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res 2013, 73:6886-6899.
21. Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB: Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 2006, 66:9308-9315.
22. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkila P, Perou CM, Horwitz KB: Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A 2012, 109:2742-2747.
23. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA: Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 2011, 128:45-55.
24. Horwitz KB, Mockus MB, Lessey BA: Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 1982, 28:633-642.
25. Pinto MP, Badtke MM, Dudevoir ML, Harrell JC, Jacobsen BM, Horwitz KB: Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. Cancer Res 2010, 70:2655-2664.
26. Joensuu K, Heikkila P, Andersson LC: Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. Cancer Lett 2008, 265:76-83.
27. Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkila P: ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast Cancer (Auckl) 2013, 7:23-34.
28. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, Tang P: The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) 2010, 4:35-41.
29. Nardulli AM, Greene GL, O'Malley BW, Katzenellenbogen BS: Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology 1988, 122:935-944.
30. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003, 78:105-118.
31. Anuka E, Gal M, Stocco DM, Orly J: Expression and roles of steroidogenic acute regulatory (StAR) protein in 'non-classical', extra-adrenal and extra-gonadal cells and tissues. Mol Cell Endocrinol 2013, 371:47-61.
32. Weilbaecher KN, Guise TA, McCauley LK: Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11:411-425.
33. Valastyan S, Weinberg RA: Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
34. Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van Gils CH, van der Wall E, van Diest PJ: Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012, 118:4929-4935.
35. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA, Breast Recurrence in Tissues Study G: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010, 12:R92.
36. Van Hooser A, Goodrich DW, Allis CD, Brinkley BR, Mancini MA: Histone H3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation. J Cell Sci 1998, 111:3497-3506.
37. Brackstone M, Townson JL, Chambers AF: Tumour dormancy in breast cancer: an update. Breast Cancer Res 2007, 9:208.
38. Peurala E, Koivunen P, Haapasaari KM, Bloigu R, Jukkola-Vuorinen A: The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 2013, 15:R5.
39. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
40. Cancer Genome Atlas N: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
41. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K: Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
42. Iorns E, Drews-Elger K, Ward TM, Dean S, Clarke J, Berry D, El Ashry D, Lippman M: A new mouse model for the study of human breast cancer metastasis. PLoS One 2012, 7:e47995.
43. Lacroix M, Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004, 83:249-289.
44. Chia S: Testing for discordance at metastatic relapse: does it matter? J Clin Oncol 2012, 30:575-576.
45. Hoefnagel L, van de Vijver M, van Slooten H-J, Wesseling P, Wesseling J, Westenend P, Bart J, Seldenrijk C, Nagtegaal I, Oudejans J, van der Valk P, van der Groep P, de Vries EG, van der Wall E, van Diest PJ: Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010, 12:R75.
46. Weigelt B, Peterse JL, van't Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer 2005, 5:591-602.
47. Iyer V, Klebba I, McCready J, Arendt LM, Betancur-Boissel M, Wu MF, Zhang X, Lewis MT, Kuperwasser C: Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. Cancer Res 2012, 72:2705-2713.
48. Cui J, Shen Y, Li R: Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med 2013, 19:197-209.
49. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007, 7:834-846.
50. Uhr JW, Pantel K: Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 2011, 108:12396-12400.
51. Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, Chung HC, Park BW: Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol 2011, 137:1123-1130.
52. Thakkar JP, Mehta DG: A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 2011, 16:276-285.
53. Zhang Y, Su H, Rahimi M, Tochihara R, Tang C: EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer 2009, 125:2021-2028.
54. Fidler IJ, Kim SJ, Langley RR: The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 2007, 101:927-936.
55. George AL, Rajoria S, Suriano R, Mittleman A, Tiwari RK: Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence. Mol Cancer 2012, 11:80.
56. Welch HG, Black WC: Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997, 127:1023-1028.